TC
ACRS icon

Trium Capital’s Aclaris Therapeutics ACRS Stock Holding History

Trium Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,912,990
Closed -$2.2M – 41
2024
Q3 		$2.2M Buy
1,912,990
+20,940
+1% +$25.7K 0.63% 32
2024
Q2 		$2.08M Buy
+1,892,050
New +$2.22M 0.26% 37

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Trium Capital's ACRS Position: Q4 2024 in Review

Trium Capital sold out of Aclaris Therapeutics (ACRS) in Q4 2024, closing a stake of 1,912,990 shares — an estimated $2.2M sold.

Trium Capital first reported a position in ACRS in Q2 2024 and held it in 2 quarters. The position peaked at $2.2M in Q3 2024. 98 funds tracked by Wall St. Rank hold ACRS as of Q4 2024.

  • Trium Capital reported no remaining Aclaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Trium Capital sold 1,912,990 Aclaris Therapeutics shares in Q4 2024, an estimated $2.2M.
  • Trium Capital first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 2 quarters.
  • Trium Capital's Aclaris Therapeutics position peaked at $2.2M in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2024.

Based on Trium Capital's 13F filing for Q4 2024, filed 15 Jan 2025.